Enalapril, Atenolol, Alendronate and DRESS Syndrome – A Case Report

Mizukawa Y, Shiohara T. Recent advances in the diagnosis and treatment of DIHS/DRESS in 2025. Allergol Int 2025; 74: 372–379. DOI: https://doi.org/10.1016/j.alit.2025.03.007

Chen CB, Hung WK, Wang CW, Lee CC, Hung SI, Chung WH. Advances in understanding of the pathogenesis and therapeutic implications of drug reaction with eosinophilia and systemic symptoms: an updated review. Front Med 2023; DOI: https://doi.org/10.3389/fmed.2023.1187937

Wei BM, Fox LP, Kaffenberger BH, Korman AM, Micheletti RG, Mostaghimi A, et al. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part II diagnosis and management. J Am Acad Dermatol 2024; 90: 911–926. DOI: https://doi.org/10.1016/j.jaad.2023.02.073

Cabañas R, Ramírez E, Sendagorta E, Alamar R, Barranco R, Blanca-López N, et al. Spanish guidelines for diagnosis, management, treatment, and prevention of DRESS syndrome. J Investig Allergol Clin Immunol 2020; 30: 229–253. DOI: https://doi.org/10.18176/jiaci.0480

Mizukawa Y, Hama N, Niihara H, Miyagawa F, Hashizume H, Tohyama M, et al. Guidelines for the management of drug‐induced hypersensitivity syndrome 2023. J Dermatol 2025; 52. DOI: https://doi.org/10.1111/1346-8138.17609

Picard D, Vellar M, Janela B, Roussel A, Joly P, Musette P. Recurrence of drug-induced reactions in DRESS patients. J Eur Acad Dermatol Venereol 2015; 29: 801–804. DOI: https://doi.org/10.1111/jdv.12419

Cabañas R, Calderón O, Ramírez E, Fiandor A, Caballero T, Heredia R, et al. Sensitivity and specificity of the lymphocyte transformation test in drug reaction with eosinophilia and systemic symptoms causality assessment. Clin Exp Allergy 2018; 48: 325–333. DOI: https://doi.org/10.1111/cea.13076

Wei BM, Fox LP, Kaffenberger BH, Korman AM, Micheletti RG, Mostaghimi A, et al. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part I. Epidemiology, pathogenesis, clinicopathological features, and prognosis. J Am Acad Dermatol 2024; 90: 885–908. DOI: https://doi.org/10.1016/j.jaad.2023.02.072

Confavreux CB, Canoui-Poitrine F, Schott AM, Ambrosi V, Tainturier V, Chapurlat RD. Persistence at 1 year of oral antiosteoporotic drugs: a prospective study in a comprehensive health insurance database. Eur J Endocrinol 2012; 166: 735–741. DOI: https://doi.org/10.1530/EJE-11-0959

Personal message. Swedish Medical Products Agency’s Adverse Reactions Department; 2025 Dec.

Descamps V, Valance A, Edlinger C, Fillet AM, Grossin M, Lebrun-Vignes B, et al. Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol 2001; 137: 301–304.

Zhu H, Ren V. Immunopathogenic insights on preferential human herpesvirus-6 reactivation in drug rash with eosinophilia and systemic symptoms: a scoping review. J Cutan Med Surg 2023; 27: 388–398. DOI: https://doi.org/10.1177/12034754231177590

Sachs B, Fatangare A, Sickmann A, Glässner A. Lymphocyte transformation test: history and current approaches. J Immunol Methods 2021; 493: 113036. DOI: https://doi.org/10.1016/j.jim.2021.113036

Chu C, Schönbrunn A, Elitok S, Kern F, Schnatbaum K, Wenschuh H, et al. T-cell proliferation assay for the detection of SARS-CoV-2-specific T-cells. Clinica Chimica Acta 2022; 532: 130–136. DOI: https://doi.org/10.1016/j.cca.2022.05.025